Hemophilia Treatment Market – Overview
Hemophilia is an inherited genetic blood disorder and holds a chronic status. People with hemophilia are likely to live with the condition throughout their life but the effects can be greatly reduced with the help of several hemophilia drug and therapeutics. The prevalence of hemophilia has increased across the globe in recent years. A higher level of awareness and high healthcare expenditure are two major factors that are driving the growth of haemophilia treatment market in the advanced countries in Americas and Europe.
Hemophilia Treatment Market is expected to reach a valuation in excess of USD 16,000 Mn by the year 2023. MRFR projects that the market will exhibit an above-average CAGR of 6.10% during 2018 to 2023.
Request Sample Copy at https://www.marketresearchfuture.com/sample_request/5688
Growing used of recombinant products is also reflecting favourably on the global market for hemophilia treatment. Recombinant products are an alternative to plasma derived products and considered relatively safer. Hemophilia drugs that are manufactured using recombinant products have proteins that are derived from genetically engineered cell lines and thereby have minimum or zero risk of contaminations. Demand for recombinant products is expected to remain high during the forecast period. Such factors are expected to support the growth of the market as well. In addition, regions such as the Middle East & Africa (MEA) and Asia Pacific (APAC) are also presenting lucrative growth opportunities to market players.
Hemophilia Treatment Market – Segmentation:
MRFR’s report also includes an in-depth segmental analysis of the global market for haemophilia treatment based on type, treatment type, end user and region. On the basis of type, the market has been segmented into hemophilia A, hemophilia B, and hemophilia C. Of these, the hemophilia A segment will continue to hold the largest share of the market over 2023. The segment is projected to reach a valuation of more than USD 12,600 Mn towards the end of review period, reflecting a healthy CAGR.
By treatment type, the market is segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, gene therapy and antifibrinolytic agents. The recombinant coagulation factor concentrates segment is expected to remain highly attractive during the assessment period. This is primarily owing to the high level of safety and efficacy offered by recombinant coagulation factor concentrates. In 2017, the segment stood at market valuation of USD 6,500 Mn.
By end user, the market is segmented into hospitals & clinics, research organization and others. By the year 2023, the hospitals & clinics segment is expected to surpass a market valuation of USD 11,000, exhibiting an impressive CAGR of 6.53%.
Hemophilia Treatment Market – Regional Analysis:
Based on regions, the hemophilia treatment market has been segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). Currently, the Americas region holds the largest share of the global haemophilia treatment market and is likely to retain its dominant position in 2018 and beyond.
North America in particular present significant growth opportunities to market owing to factors such as high healthcare expenditure and existence of an advanced healthcare system. Meanwhile, Europe has emerged as the second largest market for hemophilia treatment. Presence a large number prominent drug manufacture gives the Europe market an edge.
The market in APAC is also expected to witness a healthy growth during the forecast period. Rapid growth of the healthcare sector and introduction of favourable policies are attracting market players towards the region.
Browse Complete 158 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688
Hemophilia Treatment Market: Competitive Landscape
Bayer AG, Swedish Orphan Biovitrum AB, Pfizer Inc, Grifols International S.A, Octapharma, Baxter, F.Hoffmann-La Roche Ltd, CSL Behring, Novo Nordisk A/S, Kedrion, Sanofi and Shire are some of the key market participants mentioned in MRFR’s report.
Some Posits from TOC of Hemophilia Treatment Market Research Report – Forecast to 2023
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
TOC CONTINUED…
LIST OF TABLES:
Table 1 Hemophilia Industry Synopsis, 2017 – 2023
Table 2 Hemophilia Market Estimates And Forecast, 2017 – 2023, (USD Million)
Table 3 Hemophilia Market By Region, 2017 – 2023, (USD Million)
Table 4 Hemophilia Market By Type, 2017 – 2023, (USD Million)
Table 5 Hemophilia Market By Treatment, 2017 – 2023, (USD Million)
Table 6 Hemophilia Market By End User, 2017 – 2023, (USD Million)
Table 7 North America Hemophilia Market By Type, 2017 – 2023, (USD Million)
Table 8 North America Hemophilia Market By Treatment, 2017 – 2023, (USD Million)
Table 9 North America Hemophilia Market By End User, 2017 – 2023, (USD Million)
Table 10 US Hemophilia Market By Type, 2017 – 2023, (USD Million)
LIST OF TABLES CONTINUED…
Check Discount at https://www.marketresearchfuture.com/check-discount/5688
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688